Why Is Lilly Suing the FDA Over Retatrutide? The Biologic Lawsuit and OFA Amicus Brief, Explained
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
Eli Lilly is suing the FDA to reclassify retatrutide as a biologic rather than a traditional drug, because biologic status would give Lilly 12 years of market exclusivity instead of 5, longer protection from Medicare price negotiations, and stronger restrictions on future compounding of the medication (Big Molecule Watch, Eli Lilly Files Suit Challenging the FDA’s Drug Classification of Retatrutide).
If that does not sound like a patient story on the surface, here’s the part that makes it one. The Outsourcing Facilities Association (OFA), the trade group representing FDA-registered 503B compounding pharmacies, has been an active voice in this fight, filing amicus briefs (a Latin term for “friend of the court” briefs, which are filings from non-parties who have a stake in the outcome and want to give the court information or perspective the parties may not have presented) in compounding-related federal cases, including a brief filed at the U.S. Supreme Court in October 2025 (Cornell Law, Amicus Curiae). OFA’s position across those filings is that classification decisions that close compounding pathways undo Congress’s deliberate carve-out of compounded medications from premarket approval requirements, and that the result is reduced patient access (Brief for Amicus Curiae Outsourcing Facilities Association, U.S. Supreme Court No. 25-257). The Lilly case sits at the center of that broader question for the next generation of GLP-1 medications.
This article is a friendly tour of how the lawsuit got here, what the FDA’s position was, what the court ruled in September 2025, what Lilly is appealing now, and what it would mean for patient access. It is reporting, not legal advice or medical advice.
Who This Helps
This one is for you if you have been following the GLP-1 news and seen headlines about Lilly and the FDA in court, if you take a compounded GLP-1 medication today and want to understand what the case could mean for the broader compounding landscape, or if you are watching the retatrutide story closely because you may want to take it once it is FDA-approved.
The Backstory: How We Got Here
Retatrutide is Eli Lilly’s next-generation triple-agonist weight-loss medication, currently in Phase 3 clinical trials under the TRIUMPH program. The TRIUMPH-1 trial published in May 2026 showed up to 28.3% average weight loss at 80 weeks at the highest dose, putting retatrutide in the same range as bariatric surgery and likely making it one of the most clinically powerful GLP-1 medications when it reaches the market (AJMC, Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial).
Behind the scenes of the clinical program, Lilly has been trying to lock in the most favorable regulatory category for retatrutide before it reaches approval. The category matters because biologics and traditional drugs play by different rules in three areas that shape access and pricing for patients.
Lilly first asked the FDA to classify retatrutide as a biologic. The FDA rejected that request, ruling that retatrutide did not meet the agency’s interpretation of “biological product” under federal law. Lilly responded by filing a lawsuit in September 2024 in the U.S. District Court for the Southern District of Indiana, asking the court to overturn the FDA’s classification and require the agency to designate retatrutide as a biologic (Big Molecule Watch).
The Core Question: Drug or Biologic?
Federal law defines a “biological product” to include proteins and things “analogous” to proteins. The FDA’s interpretation required a molecule to have more than 40 alpha amino acids (the standard building blocks of proteins) to count as a protein. Retatrutide is made up of 41 amino acids, but 40 of those are alpha amino acids and 1 is a non-alpha amino acid, which the FDA had excluded from its count, leaving retatrutide just below the FDA’s threshold (Goodwin Law, District Court Sets Aside FDA’s Interpretation of Analogous to a Protein).
On September 30, 2025, the court sided with Lilly on a key technical question. The judge vacated (set aside) the FDA’s classification decision and sent the case back to the agency to come up with a clearer, uniform definition of when a protein-like molecule qualifies as “analogous” to a protein. The court did not rule that retatrutide IS a biologic. It told the FDA to redo its analysis with better-reasoned criteria, which the agency can still use to reach the same conclusion if it shows its work.
The FDA can come back with a new analysis that classifies retatrutide as a drug, if it can justify the new reasoning. Or it can come back classifying retatrutide as a biologic. Either decision can be challenged again in court. The question is unresolved.
What Biologic Status Would Actually Change for Patients
The classification question matters because biologic status carries a different set of rules in three areas patients care about. Each of these is part of why Lilly wants the biologic designation and part of why the OFA’s amicus brief argues against it.
Exclusivity Periods (12 Years vs 5 Years)
Biologics get 12 years of market exclusivity in the United States before a biosimilar (the biologic equivalent of a generic) can be approved. Traditional drugs get 5 years of exclusivity before a generic can be approved (FDA, Commemorating the 15th Anniversary of the Biologics Price Competition and Innovation Act). For retatrutide, that is a 7-year difference in how long Lilly would hold the market without lower-cost alternatives.
Medicare Price Negotiations
Under the Inflation Reduction Act (a 2022 law that, among other things, gave Medicare the authority to negotiate prices on a small number of high-spend medications), traditional drugs become eligible for Medicare price negotiation 7 years after FDA approval, with negotiated prices taking effect 9 years post-approval. Biologics become eligible 11 years after licensure, with negotiated prices applying 13 years after licensure (KFF, FAQs about the Inflation Reduction Act’s Medicare Drug Price Negotiation Program). Biologic status therefore gives a manufacturer an additional 4 years of full-price exposure before Medicare can negotiate.
Future Compounding Access
Biological products are not eligible for the 503A and 503B compounding exemptions under federal law. Traditional drugs can, under specific conditions including FDA-recognized shortages, be prepared by licensed compounding pharmacies (FDA, Notice to Compounders, Changes that Affect Compounding as of March 23, 2020). If retatrutide is classified as a biologic, that pathway is closed permanently. If it stays a drug, the future possibility of legitimate compounding remains open, subject to FDA shortage status and bulks list decisions.
What the OFA’s Position Looks Like
The OFA represents FDA-registered 503B outsourcing facilities, which compound medications under federal manufacturing standards. The group has been one of the most consistent voices arguing that classification decisions affecting compounding access are about more than the chemistry of any single molecule, and the publicly filed October 2025 OFA amicus brief at the U.S. Supreme Court (a different but closely-related case on FDA’s enforcement discretion over compounded drugs) lays out the broader OFA position in detail (Brief for Amicus Curiae Outsourcing Facilities Association, Wells Pharma of Houston v. Zyla Life Sciences, U.S. Supreme Court No. 25-257). Several arguments from that brief map directly onto the retatrutide biologic dispute:
- Federal law expressly carved out compounded medications from the premarket approval process required for other “new drugs,” reflecting Congress’s deliberate decision to allow this access route
- Compounding pharmacies and outsourcing facilities serve a critical public-health function during shortages and for patient populations whose needs are not met by commercial production
- Closing compounding pathways through reclassification “undoes Congress’s determination” to allow compounded drug access
- The current Good Manufacturing Practices (cGMP) standards that 503B outsourcing facilities follow are the same manufacturing-quality rules applied to new drug manufacturers
Applied to the retatrutide question, the implication is straightforward. If retatrutide is reclassified as a biologic, federal compounding exemptions under Sections 503A and 503B will not apply to it once it is approved, and the access pathway that compounding pharmacies have historically provided when branded supply has been short or expensive will be unavailable for the next generation of GLP-1 medications.
The amicus brief is not legally binding on any court. Its purpose is to put patient-access stakes in front of the judges deciding the case, and to make clear that the classification decision is about more than the technical chemistry of any one molecule.
Important Context: Compounded Retatrutide Today
The compounding question in this case is about the future. Retatrutide is not currently legal under standard compounding pathways. The FDA spelled this out in a March 31, 2025 letter to the National Association of Boards of Pharmacy (FDA Letter on Retatrutide in Compounded Drug Products). Because retatrutide is not the subject of a USP or NF monograph, is not a component of an FDA-approved drug, is not on the 503A bulks list, is not on the 503B bulks list, and is not on the FDA’s drug shortage list, the agency concluded that compounded retatrutide products do not qualify for the exemptions under either Section 503A or Section 503B.
Products being sold online as “compounded retatrutide” are operating outside the licensed-compounding framework. In September 2025, the FDA issued a wave of warning letters to companies marketing unapproved retatrutide and other unapproved GLP-1 products, citing unapproved-drug marketing, misbranding, and other violations. The agency has formally recommended that consumers not purchase these products and that healthcare providers discuss the risks with their patients (FDA Letter on Retatrutide in Compounded Drug Products).
The Lilly v FDA case is not about whether current gray-market retatrutide is legal. The case is about which regulatory category retatrutide will fall into once it is FDA-approved, and whether legitimate compounding pathways will be available to patients in the years that follow.
Where the Case Stands as of May 2026
The case is back at the FDA on remand. The agency has to reissue its decision on retatrutide’s classification using a clearer, uniform standard for what counts as “analogous” to a protein. Once it does, the new decision will likely face further court challenges from whichever side disagrees.
In parallel, retatrutide’s clinical timeline is moving toward approval. An NDA (New Drug Application) filing from Lilly is anticipated in late 2026, with FDA review and a potential approval decision expected in 2027 or 2028.
The classification question is being decided in parallel with the approval process, which means the rules that apply when retatrutide reaches the market depend significantly on how the case shakes out in the meantime.
What to Watch For
A few specific markers if you want to follow the story:
- The FDA’s new decision on retatrutide classification after the remand
- Any further court action in the Lilly v FDA case once that decision lands
- Lilly’s NDA filing for retatrutide approval, anticipated in late 2026
- FDA enforcement guidance on compounded GLP-1 products as retatrutide approaches market
Final Takeaway
The Lilly v FDA retatrutide biologic lawsuit is one of those regulatory cases that doesn’t look like a patient story on the surface, but is actually one of the most consequential cases for the next chapter of GLP-1 access. Whether retatrutide ends up classified as a drug or as a biologic will shape Lilly’s exclusivity timeline, Medicare’s ability to negotiate the price, and the legal pathways pharmacies can use to compound it during any future shortages.
For now, the case is unresolved. The court told the FDA its previous reasoning was not enough, but did not tell the FDA how it has to come out the other side. The agency is reconsidering. OFA is making sure patient access is part of the conversation in front of the judge.
The story is worth following, and the people advocating for patient access in this fight are doing so loudly. The decisions that come out of this case will shape what GLP-1 access actually looks like for the rest of the decade.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Sources
Keep Reading
Retatrutide shows major Phase 3 weight-loss results but remains investigational. Learn what’s real in 2026 and why social ads can be misleading.
Eli Lilly claims B12 in compounded GLP-1s creates an impurity. We break down what the data shows, what's missing, and whether you should worry.
Lab testing finds many grey-market peptides miss their purity claims, with heavy metals and bacterial contamination in samples. Here is what to know.
Categories
Curated by
